Dr. Philip Leighton
Sr. Director, Molecular Biology at Ligand Pharmaceuticals Incorporated
Dr. Leighton is Senior Director of Molecular Biology at Ligand Pharmaceuticals in Emeryville, CA. He received his Ph.D in Molecular Biology from Princeton University, followed by post-doctoral studies at the University of California, San Francisco. At Ligand, he is responsible for the development and validation of the OmniChicken® portion of the OmniAb® platform for the production of human antibodies in transgenic chickens. In addition to OmniChickens expressing normal human antibodies, he has more recently developed OmniClic® chickens expressing a common light chain for bispecific antibody discovery. Currently under development are OmniDabTM chickens expressing single domain antibodies, and the OmniTaurTM platform for heavy chains with ultralong CDR-H3s. OmniChickens are currently being used in a number of programs by pharmaceutical industry partners.